147 related articles for article (PubMed ID: 32236621)
1. Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer.
Kumamoto T; Yamada K; Yoshida S; Aoki K; Hirooka S; Eto K; Yanaga K; Yoshida K
Int J Oncol; 2020 Jun; 56(6):1529-1539. PubMed ID: 32236621
[TBL] [Abstract][Full Text] [Related]
2. Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Yan H; Hu K; Wu W; Li Y; Tian H; Chu Z; Koeffler HP; Yin D
PLoS One; 2016; 11(8):e0159954. PubMed ID: 27532268
[TBL] [Abstract][Full Text] [Related]
3. Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Ito D; Yogosawa S; Mimoto R; Hirooka S; Horiuchi T; Eto K; Yanaga K; Yoshida K
Cancer Sci; 2017 Aug; 108(8):1565-1573. PubMed ID: 28502078
[TBL] [Abstract][Full Text] [Related]
4. Enforced dual-specificity tyrosine-regulated kinase 2 expression by adenovirus-mediated gene transfer inhibits tumor growth and metastasis of colorectal cancer.
Imaizumi Y; Yoshida S; Kanegae Y; Eto K; Yoshida K
Cancer Sci; 2022 Mar; 113(3):960-970. PubMed ID: 34932844
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Imawari Y; Mimoto R; Hirooka S; Morikawa T; Takeyama H; Yoshida K
Cancer Sci; 2018 Feb; 109(2):363-372. PubMed ID: 29193658
[TBL] [Abstract][Full Text] [Related]
6. Dual-specificity tyrosine-regulated kinase 2 exerts anti-tumor effects by induction of G1 arrest in lung adenocarcinoma.
Harada E; Yoshida S; Imaizumi Y; Kawamura A; Ohtsuka T; Yoshida K
Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130600. PubMed ID: 38508285
[TBL] [Abstract][Full Text] [Related]
7. Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Wang Y; Wu Y; Miao X; Zhu X; Miao X; He Y; Zhong F; Ding L; Liu J; Tang J; Huang Y; Xu X; He S
Int J Biol Macromol; 2015 Nov; 81():809-17. PubMed ID: 26341817
[TBL] [Abstract][Full Text] [Related]
8. Intestinal PPARα Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6.
Luo Y; Xie C; Brocker CN; Fan J; Wu X; Feng L; Wang Q; Zhao J; Lu D; Tandon M; Cam M; Krausz KW; Liu W; Gonzalez FJ
Gastroenterology; 2019 Sep; 157(3):744-759.e4. PubMed ID: 31154022
[TBL] [Abstract][Full Text] [Related]
9. Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Yokoyama-Mashima S; Yogosawa S; Kanegae Y; Hirooka S; Yoshida S; Horiuchi T; Ohashi T; Yanaga K; Saruta M; Oikawa T; Yoshida K
Cancer Lett; 2019 Jun; 451():100-109. PubMed ID: 30851422
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Associated Macrophages Promote Epigenetic Silencing of Gelsolin through DNA Methyltransferase 1 in Gastric Cancer Cells.
Wang HC; Chen CW; Yang CL; Tsai IM; Hou YC; Chen CJ; Shan YS
Cancer Immunol Res; 2017 Oct; 5(10):885-897. PubMed ID: 28835422
[TBL] [Abstract][Full Text] [Related]
11. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Xu XL; Yu J; Zhang HY; Sun MH; Gu J; Du X; Shi DR; Wang P; Yang ZH; Zhu JD
World J Gastroenterol; 2004 Dec; 10(23):3441-54. PubMed ID: 15526363
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of serum/glucocorticoid regulated kinase 1 in colorectal tumours is largely independent of promoter hypermethylation.
Lessi F; Beggs A; de Palo M; Anti M; Macarone Palmieri R; Francesconi S; Gomes V; Bevilacqua G; Tomlinson I; Segditsas S
PLoS One; 2010 Nov; 5(11):e13840. PubMed ID: 21079778
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma.
Semba S; Itoh N; Ito M; Youssef EM; Harada M; Moriya T; Kimura W; Yamakawa M
Clin Cancer Res; 2002 Dec; 8(12):3824-31. PubMed ID: 12473596
[TBL] [Abstract][Full Text] [Related]
14. MPP3 inactivation by promoter CpG islands hypermethylation in colorectal carcinogenesis.
Feng X; Chen K; Ye S; Wang H; Wei G; Tan W; Cheng S; Zhang Y; Liu S; Zhou Y
Cancer Biomark; 2012; 11(2-3):99-106. PubMed ID: 23011156
[TBL] [Abstract][Full Text] [Related]
15. Semaphorin-3F functions as a tumor suppressor in colorectal cancer due to regulation by DNA methylation.
Gao X; Tang C; Shi W; Feng S; Qin W; Jiang T; Sun Y
Int J Clin Exp Pathol; 2015; 8(10):12766-74. PubMed ID: 26722466
[TBL] [Abstract][Full Text] [Related]
16. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
[TBL] [Abstract][Full Text] [Related]
17. Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
Mimoto R; Imawari Y; Hirooka S; Takeyama H; Yoshida K
Oncogene; 2017 Mar; 36(13):1862-1872. PubMed ID: 27721402
[TBL] [Abstract][Full Text] [Related]
18. Kindlin-2 interacts with and stabilizes DNMT1 to promote breast cancer development.
Wang P; Chu W; Zhang X; Li B; Wu J; Qi L; Yu Y; Zhang H
Int J Biochem Cell Biol; 2018 Dec; 105():41-51. PubMed ID: 30287284
[TBL] [Abstract][Full Text] [Related]
19. NUSAP1 gene silencing inhibits cell proliferation, migration and invasion through inhibiting DNMT1 gene expression in human colorectal cancer.
Han G; Wei Z; Cui H; Zhang W; Wei X; Lu Z; Bai X
Exp Cell Res; 2018 Jun; 367(2):216-221. PubMed ID: 29608915
[TBL] [Abstract][Full Text] [Related]
20. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth.
Wang Y; He T; Herman JG; Linghu E; Yang Y; Fuks F; Zhou F; Song L; Guo M
Clin Epigenetics; 2017; 9():115. PubMed ID: 29075358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
